CoChat
Sign Up
Cited by 215Extracellular vesicles in diseaseMicroRNA in disease regulationMesenchymal stem cell research

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379

Open access
O’Brien, K. P., Khan, S., Gilligan, K. E., Zafar, H., Lalor, P., Glynn, C., O’Flatharta, C., Ingoldsby, H., Dockery, P., De Bhulbh, A., Schweber, J. R., St John, K., Leahy, M., Murphy, J. M., Gallagher, W. M., O’Brien, T., Kerin, M. J., Dwyer, R. M.·2018·Oncogene
DOI 10.1038/s41388-017-0116-9
Open this paper in CoChat — free account

Abstract

Adult Mesenchymal Stem Cells (MSCs) have a well-established tumor-homing capacity, highlighting potential as tumor-targeted delivery vehicles. MSCs secrete extracellular vesicle (EV)-encapsulated microRNAs, which play a role in intercellular communication. The aim of this study was to characterize a potential tumor suppressor microRNA, miR-379, and engineer MSCs to secrete EVs enriched with miR-379 for in vivo therapy of breast cancer. miR-379 expression was significantly reduced in lymph node metastases compared to primary tumor tissue from the same patients. A significant reduction in the rate of tumor formation and growth in vivo was observed in T47D breast cancer cells stably expressing miR-379. In more aggressive HER2-amplified HCC-1954 cells, HCC-379 and HCC-NTC tumor growth rate in vivo was similar, but increased tumor necrosis was observed in HCC-379 tumors. In response to elevated miR-379, COX-2 mRNA and protein was also significantly reduced in vitro and in vivo. MSCs were successfully engineered to secrete EVs enriched with miR-379, with the majority found to be of the appropriate size and morphology of exosomal EVs. Administration of MSC-379 or MSC-NTC cells, or EVs derived from either cell population, resulted in no adverse effects in vivo. While MSC-379 cells did not impact tumor growth, systemic administration of cell-free EVs enriched with miR-379 was demonstrated to have a therapeutic effect. The data presented support miR-379 as a potent tumor suppressor in breast cancer, mediated in part through regulation of COX-2. Exploiting the tumor-homing capacity of MSCs while engineering the cells to secrete EVs enriched with miR-379 holds exciting potential as an innovative therapy for metastatic breast cancer.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41388-017-0116-9

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 54 references

Research works printed but not linked: 2

  1. Khan S, Brougham CL, Ryan J, Sahrudin A, O’Neill G, Wall D, et al. miR-379 regulates cyclin B1 expression and is decreased in breast cancer. PLoS ONE. 2013;8:e68753. · DOI
  2. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, et al. Monocyte chemotactic protein-1 (MCP-1) secreted by primary breast tumors stimulates migration of Mesenchymal Stem Cells (MSCs). Clin Cancer Res. 2007;13:5020–7. · DOI

Cited by

Sorted by citations

Related

See all

Metadata

Authors
O’Brien, K. P., Khan, S., Gilligan, K. E., Zafar, H., Lalor, P., Glynn, C., O’Flatharta, C., Ingoldsby, H., Dockery, P., De Bhulbh, A., Schweber, J. R., St John, K., Leahy, M., Murphy, J. M., Gallagher, W. M., O’Brien, T., Kerin, M. J., & Dwyer, R. M.
Affiliations
  • Ollscoil na Gaillimhe – University of Galway (IE)
  • University Hospital Galway (IE)
  • University College Dublin (IE)
Corresponding author
Dwyer, R. M.
ORCID
Venue
Oncogene
Publisher
Springer Science and Business Media LLC
Published
2018-01-25
Volume
37
Issue
16
Pages
2137-2149
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
DOI
10.1038/s41388-017-0116-9
OpenAlex
W2793133729
Cited by
215
References
54
Citations by year
2026: 11 · 2025: 23 · 2024: 21 · 2023: 38 · 2022: 41 · 2021: 33 · 2020: 29 · 2019: 12 · 2018: 7
FWCI
7.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
  • Arrow@dit (Dublin Institute of Technology) (acceptedVersion)
  • ARAN (University of Galway Research Repository) (Ollscoil na Gaillimhe – University of Galway) (acceptedVersion, cc-by-nc-nd)
  • ARAN (University of Galway Research Repository) (Ollscoil na Gaillimhe – University of Galway) (acceptedVersion, cc-by)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
Keywords
mesenchymal stem cells, extracellular vesicles, tumor-targeted delivery, breast cancer, tumor suppressor microRNA, cyclooxygenase-2, HER2-amplified breast cancer, lymph node metastasis, cell-free therapy, exosomes
MeSH terms
Extracellular Vesicles, Animals, Breast Neoplasms, Cells, Cultured, Drug Compounding, Female, Humans, Lymphatic Metastasis, Mice, Inbred BALB C, Mice, Nude, Neoplasm Metastasis, Genetic Therapy, Gene Expression Regulation, Neoplastic, Drug Delivery Systems, Xenograft Model Antitumor Assays, MicroRNAs, Therapies, Investigational, Mesenchymal Stem Cell Transplantation, Mice, Adult Stem Cells, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review